Fulvestrant (ICI 182780) CAS 129453-61-8 API Factory High Quality
Manufacturer Supply with High Purity and Stable Quality
Name: Fulvestrant
CAS: 129453-61-8
Fulvestrant is used in the treatment of hormone-sensitive advanced breast cancer in postmenopausal women.
API High Quality, Commercial Production
Chemical Name | Fulvestrant |
Synonyms | (7α,17β)-7-[9-[(4,4,5,5,5-Pentafluorpentyl)sulfinyl]nonyl]estra-1,3,5(10)-trien-3,17-diol; ICI 182780 |
CAS Number | 129453-61-8 |
CAT Number | RF-API81 |
Stock Status | In Stock, Production Scale Up to Hundreds of Kilograms |
Molecular Formula | C32H47F5O3S |
Molecular Weight | 606.77 |
Melting Point | 104.0~106.0℃ |
Solubility | Soluble in Methanol, Ethanol; Insoluble in Water |
Brand | Ruifu Chemical |
Item | Specifications |
Appearance | White to Off-White Crystalline Powder |
Identification | By IR, HPLC |
Specific Optical Rotation | +108.0° to +115.0° |
Loss on Drying | ≤0.50% |
Residue on Ignition | ≤0.10% |
6-Keto-Fulvestrant | ≤0.10% |
6,7-Fulvestrant | ≤0.10% |
Fulvestrant Sulfone | ≤0.20% |
Fulvestrant Extended | ≤0.30% |
Fulvestrant Sterol Dimmer | ≤0.80% |
Any Individual Unspecified Impurity | ≤0.10% |
Total Impurities | ≤1.0% |
Fulvestrant A | 42.0%~48.0% |
Fulvestrant B | 52.0%~58.0% |
DMF | ≤620ppm |
Heavy Metals | ≤10ppm |
Assay | 97.0%~102.0% (on dried basis) |
Storage | Preserve in well-closed light-resistant containers store refrigerated at 2~8℃ |
Test Standard | United States Pharmacopoeia (USP) Standard |
Usage | Estrogen Receptor Antagonist |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.


Fulvestrant (ICI-182780) CAS 129453-61-8, is a muscle injection drug developed by the company AstraZeneca and is used in the treatment of hormone-sensitive advanced breast cancer in postmenopausal women. Fulvestrant is the only antiestrogen drug that can be widely clinically used following unsuccessful tamoxifen treatment. This drug is a type of endocrine therapy, so it will not cause any adverse effects commonly seen in chemotherapy, giving it relatively good patient compliance. Multiple clinical trials have found that 250mg Fulvestrant is effective and consistently safe as a second line of treatment for advanced breast cancer. Fulvestrant is a synthetic Estrogen Receptor (ER) Antagonist with IC50 of 0.94 nM in a cell-free assay. Fulvestrant also induces autophagy and apoptosis and has antitumor activity.
-
Favipiravir CAS 259793-96-9 T-705 Purity ≥99.0%...
-
Fulvestrant (ICI 182780) CAS 129453-61-8 API Fa...
-
Cisatracurium Besylate CAS 96946-42-8 Assay 95....
-
Dantrolene Sodium Salt Hydrate CAS 14663-23-1 A...
-
Darifenacin Hydrobromide Darifenacin HBr CAS 13...
-
Sofosbuvir CAS 1190307-88-0 Purity ≥99.0% (HPLC)
-
Sorafenib CAS 284461-73-0 Purity ≥99.0% (HPLC) ...
-
Sitagliptin Phosphate Monohydrate CAS 654671-77...
-
Tolvaptan CAS 150683-30-0 API Purity >99.0% (HPLC)
-
Perindopril Erbumine CAS 107133-36-8 Purity >99...
-
Lapatinib Base CAS 231277-92-2 Purity ≥99.0% (H...
-
Imatinib Mesylate CAS 220127-57-1 Assay 98.0%~1...
-
Gabapentin CAS 60142-96-3 Purity >99.5% (HPLC) ...
-
CAS 842133-18-0 Purity ≥99.0% (HPLC) Type 2 Dia...
-
Cefotaxime Sodium Salt CAS 64485-93-4 Assay ≥91...
-
Bicalutamide CAS 90357-06-5 API Factory High Qu...